Review: Some Nonpharmacologic Tx Effective in Peds GI Disorders

This article originally appeared here.
Share this content:
Review: Some Nonpharmacologic Tx Effective in Peds GI Disorders
Review: Some Nonpharmacologic Tx Effective in Peds GI Disorders

MONDAY, Feb. 9, 2015 (HealthDay News) -- Certain nonpharmacologic treatments are effective in pediatric abdominal pain-related functional gastrointestinal disorders (AP-FGIDs), according to a review published online Feb. 9 in Pediatrics.

Juliette M.T.M. Rutten, M.D., from Emma's Children's Hospital in Amsterdam, and colleagues conducted a systematic review of the literature relating to nonpharmacologic interventions for pediatric AP-FGIDs. Data were included from 24 randomized controlled trials that included 1,390 children.

The researchers observed significant improvement of abdominal pain after hypnotherapy versus standard care/wait list approaches and after cognitive behavioral therapy versus control/wait list approaches. At the six-month follow-up only, written self-disclosure improved pain frequency. Significantly more treatment responders were seen with Lactobacillus rhamnosus GG (LGG) and VSL#3 versus placebo (LGG relative risk, 1.31; VSL#3 P < 0.05). Irritable bowel syndrome symptom frequency was significantly improved with guar gum but there was no effect seen for other fiber supplements or a lactose-free diet. Compared with a wait-list approach, yoga was not associated with a significant decrease in functional disability. There were no reports of serious adverse events. Evidence quality was found to be very low to moderate.

"Although high-quality studies are lacking, some evidence shows efficacy of hypnotherapy, cognitive behavioral therapy, and probiotics (LGG and VSL#3) in pediatric AP-FGIDs," the authors write.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

Social, Communication Delays With False-Negative on M-CHAT

Social, Communication Delays With False-Negative on M-CHAT

Delays for those who pass M-CHAT screening at 18 months but are later diagnosed with ASD

FDA Approves Aimovig to Prevent Migraines

FDA Approves Aimovig to Prevent Migraines

Patients taking Aimovig reported one to two fewer monthly migraine days than those taking pacebo

Risk of Dementia Up for Older Adults With Lowest Wealth

Risk of Dementia Up for Older Adults With ...

Increased risk seen independent of education, index of multiple deprivation, health indicators

is free, fast, and customized just for you!

Already a member?

Sign In Now »